The literature also suggests that some tyrosine‐kinase inhibitors, such as sunitinib and sorafenib, have an associated risk of bleeding; thus, patients with known CNS metastases have also been generally excluded from clinical trials investigating these agents.181 These agents target the VEGF and platelet‐derived growth factor receptors (PDGFR), among others, to inhibit angiogenesis and halt tumor growth, invasion, and metastasis. Here, VEGFA is linked to neoplasm.